Valproic acid is under clinical development by Cereno Scientific and currently in Phase II for Pulmonary Arterial Hypertension. According to GlobalData, Phase II drugs for Pulmonary Arterial Hypertension have a 61% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Valproic acid’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Valproic acid overview
Valproic acid (CS-1) is under development for the treatment of pulmonary arterial hypertension. It is administered through oral route as capsule. CS-1 is an enhancer of t-PA production and inhibitor of PAI-1 production. The drug candidate acts by targeting histone deacetylase (HDAC). It is a controlled release formulation of sodium valproate.
It was also under development for the treatment of thrombosis.
Cereno Scientific overview
Cereno Scientific is a biotechnology company. It operates as a developer of preventive drugs that normalize the body’s own defense system against blood clots. The company develops drugs in the therapeutic area of thrombosis-related cardiovascular diseases. Cereno Scientific offers pipeline products such as CS1 and NCE. Its CS1 is being developed for the treatment of fibrinolysis. CS1 increases the production of tissue plasminogen activator (t-PA) and reduces the production plasminogen activator inhibitor-1 (PAI-1) that acts as inhibitor of t-PA. Its therapy enables to only act on clots, without affecting the entire body. The company works in partnership with Galenica AB, to develop unique formulation of CS1. Cereno Scientific is headquartered in Gothenburg, Vastra Gotland, Sweden.
For a complete picture of Valproic acid’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - Valproic Acid in Pulmonary Arterial Hypertension
Premium Insights
The gold standard of business intelligence.
